CR9215A - Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos - Google Patents

Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos

Info

Publication number
CR9215A
CR9215A CR9215A CR9215A CR9215A CR 9215 A CR9215 A CR 9215A CR 9215 A CR9215 A CR 9215A CR 9215 A CR9215 A CR 9215A CR 9215 A CR9215 A CR 9215A
Authority
CR
Costa Rica
Prior art keywords
substituted
processes
preparation
derivatives
naftilindol
Prior art date
Application number
CR9215A
Other languages
English (en)
Inventor
Vladimir A Dragan
John Richard Potoski
Wayne G Mcmahon
Jean Louise Helow
Xinxu Shi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9215A publication Critical patent/CR9215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona procesos para la preparacion de derivados de naftilindol sustituidos de formula (I) que pueden usarse como inhibidores del inhibidor del activador de plasminogeno-l (PAI-I). En ciertas realizaciones de la invencion, los procesos implican reacciones que incluyen uno o mas de una oxidacion de Oppenauer, una sintesis de indol de Fischer, una escision de eter metilico o acoplamiento de un metiltetrazol sustituido con un naftol sustituido.
CR9215A 2005-01-27 2007-06-28 Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos CR9215A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64761805P 2005-01-27 2005-01-27

Publications (1)

Publication Number Publication Date
CR9215A true CR9215A (es) 2007-11-23

Family

ID=36570379

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9215A CR9215A (es) 2005-01-27 2007-06-28 Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos

Country Status (21)

Country Link
US (2) US7323483B2 (es)
EP (1) EP1856104A1 (es)
JP (1) JP2008528618A (es)
KR (1) KR20070103744A (es)
CN (1) CN101111491A (es)
AR (1) AR053437A1 (es)
AU (1) AU2006208021A1 (es)
BR (1) BRPI0606871A2 (es)
CA (1) CA2595376A1 (es)
CR (1) CR9215A (es)
GT (1) GT200600032A (es)
HN (1) HN2006003347A (es)
IL (1) IL183712A0 (es)
MX (1) MX2007008952A (es)
NI (1) NI200700188A (es)
NO (1) NO20072879L (es)
PE (1) PE20061200A1 (es)
RU (1) RU2007121255A (es)
TW (1) TW200637850A (es)
WO (1) WO2006081455A1 (es)
ZA (1) ZA200706203B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092207A1 (en) * 2006-02-03 2007-08-16 Wyeth Compositions for the delivery of substituted naphthyl indole derivatives and methods of their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903206A1 (en) 1989-09-07 1991-03-13 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing¹lipoxygenase-inhibiting compounds
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
IL101785A0 (en) 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL109568A0 (en) 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
PL320010A1 (en) 1995-09-01 1997-09-01 Lilly Co Eli Indolyllic antagonists of neuropeptide y receptors
EP0922028A1 (en) 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
US6703527B2 (en) 2001-05-24 2004-03-09 Nikken Chemicals Co., Ltd. Method for oxidation of allyl alcohol
TW591020B (en) * 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)

Also Published As

Publication number Publication date
NI200700188A (es) 2008-05-09
US7323483B2 (en) 2008-01-29
ZA200706203B (en) 2009-12-30
CA2595376A1 (en) 2006-08-03
HN2006003347A (es) 2011-03-30
GT200600032A (es) 2006-11-14
JP2008528618A (ja) 2008-07-31
WO2006081455A1 (en) 2006-08-03
US20080071091A1 (en) 2008-03-20
NO20072879L (no) 2007-06-26
TW200637850A (en) 2006-11-01
AR053437A1 (es) 2007-05-09
MX2007008952A (es) 2007-09-18
US20060183917A1 (en) 2006-08-17
BRPI0606871A2 (pt) 2009-07-21
IL183712A0 (en) 2007-09-20
AU2006208021A1 (en) 2006-08-03
KR20070103744A (ko) 2007-10-24
PE20061200A1 (es) 2006-12-19
EP1856104A1 (en) 2007-11-21
CN101111491A (zh) 2008-01-23
RU2007121255A (ru) 2009-03-10

Similar Documents

Publication Publication Date Title
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
ECSP088222A (es) Agonistas de receptores adrenérgicos alfa2c funcionalmente selectivos
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
DOP2010000178A (es) Peptidil nitrilos como inhibidores de dipeptidil peptidasa i
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
ECSP10010722A (es) Compuestos orgánicos
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
CR20110135A (es) INHIBIDORES DE cMET
BRPI0606379A2 (pt) triazolftalazinas
CL2011002433A1 (es) Compuestos tetraciclicos, inhibidores de alk; composicion farmaceutica que comprende dichos compuestos, utiles en la profilaxis o el tratamiento de cancer, metastasis de cancer, depresion o un trastorno de la funcion cognitiva.
ECSP10010246A (es) Inhibidores de beta-lactamasa
ECSP099529A (es) Inhibidores de cinasa mapk/erk
NI201000059A (es) Inhibidores de la cinasa c-fms.
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CR9828A (es) Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
UY30801A1 (es) Compuestos calciliticos
CR20110075A (es) Agentes antifúngicos
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
CR9215A (es) Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos
ECSP13012520A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)